5/10/2025
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 34 Researches
7.9
USERS' SCORE
Good
Based on 1 Review
8.4
Top Medical Research Studies
9
We developed a folic acid-targeted liposome system to improve the delivery of sorafenib, a drug used in treating liver cancer. Through various techniques, we created liposomes loaded with sorafenib and evaluated their effects on liver cancer cells. Our results showed that this targeted system effectively inhibited cancer cell growth and induced apoptosis in vitro. Additionally, in a liver xenograft model, it successfully slowed tumor progression. Overall, our findings suggest that this targeted delivery method could enhance liver cancer therapy while minimizing side effects.
Read More
9
Folate-targeted nanoparticle therapy
We explored the potential of mesoporous silica nanoparticles (MSNs) enhanced with folic acid (FA) to deliver the chemotherapy drug epirubicin (EPI) effectively in breast cancer treatment.
Our research showed that this targeted delivery system significantly inhibited cancer cell growth both in laboratory settings and in mice. Notably, it encouraged cancer cell death through various molecular pathways while avoiding toxicity in other organs.
These findings suggest that folic acid's targeting ability may greatly enhance the effectiveness of anticancer therapies like epirubicin.
Our research showed that this targeted delivery system significantly inhibited cancer cell growth both in laboratory settings and in mice. Notably, it encouraged cancer cell death through various molecular pathways while avoiding toxicity in other organs.
These findings suggest that folic acid's targeting ability may greatly enhance the effectiveness of anticancer therapies like epirubicin.
Read More
8
We explored how zinc levels impact cancer cells and immune function, particularly focusing on macrophages, which are crucial for our body’s defense against tumors. Our research revealed that cancer cells often have decreased expression of specific genes tied to immune response, and this links to resistance against therapies designed to unblock immune checkpoints.
By upregulating a zinc importer known as SLC39A9, these cancer cells manage to hoard zinc for themselves, leaving the surrounding tumor microenvironment (TME) depleted of this vital nutrient. This competition for zinc results in macrophages becoming zinc-starved, which diminishes their ability to perform essential tasks like engulfing and destroying cancer cells.
Interestingly, we found that when we replenished zinc levels in the TME—through a dietary intervention—these macrophages could regain their pro-phagocytic function. This change significantly improved the response of certain tumors to immunotherapy treatments. Notably, T cells weren’t required for this transformation, indicating that macrophages alone play a pivotal role.
Our results are clinically relevant, showing that cancer patients with reduced zinc levels in their body tend to experience worse outcomes. Overall, we identified a new mechanism by which cancer cells can disrupt immune function, highlighting zinc’s critical role in both tumor environments and immunotherapy effectiveness.
By upregulating a zinc importer known as SLC39A9, these cancer cells manage to hoard zinc for themselves, leaving the surrounding tumor microenvironment (TME) depleted of this vital nutrient. This competition for zinc results in macrophages becoming zinc-starved, which diminishes their ability to perform essential tasks like engulfing and destroying cancer cells.
Interestingly, we found that when we replenished zinc levels in the TME—through a dietary intervention—these macrophages could regain their pro-phagocytic function. This change significantly improved the response of certain tumors to immunotherapy treatments. Notably, T cells weren’t required for this transformation, indicating that macrophages alone play a pivotal role.
Our results are clinically relevant, showing that cancer patients with reduced zinc levels in their body tend to experience worse outcomes. Overall, we identified a new mechanism by which cancer cells can disrupt immune function, highlighting zinc’s critical role in both tumor environments and immunotherapy effectiveness.
Read More
Most Useful Reviews
7.5
Easy to swallow
1 people found this helpful
I love these petite multivitamins. Having stage four metastatic breast cancer, I take these to ensure I obtain the necessary vitamins. They are easy to swallow, with no aftertaste and dissolve quickly, unlike other multivitamins that upset my stomach. The price is also reasonable.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 34 Researches
7.9
- All Researches
9.5
We constructed a zebrafish model to explore how a unique version of the PML-RARA protein, linked to acute promyelocytic leukemia (APL), might respond to treatment with all-trans retinoic acid (ATRA). This model allowed us to examine whether ATRA, a derivative of vitamin A, could be effective for patients with atypical APL characteristics.
In our findings, we observed that the response of the new PML-RARA isoform to ATRA treatment was similar to classical isoforms seen in the condition. We also found that ATRA worked well in this model, leading to favorable results for the treated patient, who reached complete remission shortly after starting therapy with ATRA and arsenic trioxide (ATO).
These results highlight the promising potential of vitamin A derivatives in cancer treatment, especially in various forms of APL. It's encouraging to see that ATRA can lead to substantial recovery, further supporting its use in clinical settings alongside other therapies.
In our findings, we observed that the response of the new PML-RARA isoform to ATRA treatment was similar to classical isoforms seen in the condition. We also found that ATRA worked well in this model, leading to favorable results for the treated patient, who reached complete remission shortly after starting therapy with ATRA and arsenic trioxide (ATO).
These results highlight the promising potential of vitamin A derivatives in cancer treatment, especially in various forms of APL. It's encouraging to see that ATRA can lead to substantial recovery, further supporting its use in clinical settings alongside other therapies.
Read More
9.5
Promising APL treatment outcomes observed
We aimed to understand the effectiveness of a combination treatment involving all-trans retinoic acid (ATRA), arsenic trioxide (ATO), and gemtuzumab ozogamicin (GO) for patients with acute promyelocytic leukemia (APL). This was a phase 2 trial involving newly diagnosed APL patients, where ATRA and ATO were used to induce remission.
The results were promising, as we observed a complete remission rate of 93.8% among the participants. Furthermore, 97.1% of those who achieved remission had no measurable residual disease, indicating a strong initial response to the treatment regimen.
Over a median follow-up of about 62 months, the 5-year survival rates were also impressive, with event-free survival at 92.4%, disease-free survival at 93.6%, and overall survival at 93.1%. We noted some side effects, including elevated liver enzymes and infections, but there were no severe complications like veno-occlusive disease.
While the study highlights the benefits of ATRA in this combination treatment, we must clarify that we cannot specifically isolate the effect of vitamin A, as it was part of a broader therapeutic approach. Nonetheless, the combination of ATRA with other agents showed significant success in treating APL, reinforcing the importance of multifaceted cancer therapies.
The results were promising, as we observed a complete remission rate of 93.8% among the participants. Furthermore, 97.1% of those who achieved remission had no measurable residual disease, indicating a strong initial response to the treatment regimen.
Over a median follow-up of about 62 months, the 5-year survival rates were also impressive, with event-free survival at 92.4%, disease-free survival at 93.6%, and overall survival at 93.1%. We noted some side effects, including elevated liver enzymes and infections, but there were no severe complications like veno-occlusive disease.
While the study highlights the benefits of ATRA in this combination treatment, we must clarify that we cannot specifically isolate the effect of vitamin A, as it was part of a broader therapeutic approach. Nonetheless, the combination of ATRA with other agents showed significant success in treating APL, reinforcing the importance of multifaceted cancer therapies.
Read More
9.5
Nanoparticle-assisted targeted cancer therapy
We explored the use of nanosecond laser pulses combined with doxorubicin-loaded gold nanoparticles (AuNPs) to target folate receptor-positive cancer cells. This innovative method allowed for the efficient release of the drug while inducing localized cell damage through thermal effects.
By testing different nanoparticle concentrations and laser settings, we observed near-complete tumor cell destruction in pinpointed areas, sparing nearby healthy cells. The results emphasized the potential of this approach for developing safer and more effective cancer therapies.
By testing different nanoparticle concentrations and laser settings, we observed near-complete tumor cell destruction in pinpointed areas, sparing nearby healthy cells. The results emphasized the potential of this approach for developing safer and more effective cancer therapies.
Read More
9.5
We examined a new approach to enhance cancer treatment by developing targeted nanogels using folic acid to deliver 5-aminolevulinic acid (5-ALA) more effectively.
By using special nanoparticles, we found that these nanogels significantly improved the delivery of 5-ALA to tumor cells, enhancing the effectiveness of photodynamic therapy.
Our in vivo experiments indicated that these nanogels notably reduced the growth of skin cancer.
Overall, this innovative delivery system shows great promise in boosting the therapeutic effects of 5-ALA against skin cancer.
By using special nanoparticles, we found that these nanogels significantly improved the delivery of 5-ALA to tumor cells, enhancing the effectiveness of photodynamic therapy.
Our in vivo experiments indicated that these nanogels notably reduced the growth of skin cancer.
Overall, this innovative delivery system shows great promise in boosting the therapeutic effects of 5-ALA against skin cancer.
Read More
9
We observed that certain types of Acute Myeloid Leukemia (AML), specifically acute erythroleukemia and acute megakaryocytic leukemia, have a concerningly short median survival and limited effective treatment options. Our exploration focused on understanding the role of the transcription factor GATA1, which is crucial for the survival of cells in these leukemia subtypes. Remarkably, we discovered that a compound known as Fenretinide (or 4-HPR), a synthetic derivative of vitamin A, can target and induce loss of GATA1 in these AML cells.
As we delved into the study, we found that treating M6 AML cells with low concentrations of 4-HPR led to significant cytotoxic effects, akin to reducing GATA1 levels through genetic methods. This indicates that 4-HPR could act similar to a targeted therapy, directly impacting the survival of these cancer cells. Further, we were encouraged to see that 4-HPR not only performed effectively on its own but also enhanced the effectiveness of existing treatments like Azacytidine and Venetoclax, which typically struggle against drug resistance.
Our findings suggest that 4-HPR might represent a promising therapeutic avenue for patients with M6 and M7 AML, paving the way for its potential inclusion as a standard treatment option in the near future. The safety profile of Fenretinide, established through numerous clinical trials, further strengthens the case for its application in the combat against these aggressive forms of leukemia.
As we delved into the study, we found that treating M6 AML cells with low concentrations of 4-HPR led to significant cytotoxic effects, akin to reducing GATA1 levels through genetic methods. This indicates that 4-HPR could act similar to a targeted therapy, directly impacting the survival of these cancer cells. Further, we were encouraged to see that 4-HPR not only performed effectively on its own but also enhanced the effectiveness of existing treatments like Azacytidine and Venetoclax, which typically struggle against drug resistance.
Our findings suggest that 4-HPR might represent a promising therapeutic avenue for patients with M6 and M7 AML, paving the way for its potential inclusion as a standard treatment option in the near future. The safety profile of Fenretinide, established through numerous clinical trials, further strengthens the case for its application in the combat against these aggressive forms of leukemia.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.4
- All Reviews
- Positive Reviews
- Negative Reviews
7.5
Easy to swallow
1 people found this helpful
I love these petite multivitamins. Having stage four metastatic breast cancer, I take these to ensure I obtain the necessary vitamins. They are easy to swallow, with no aftertaste and dissolve quickly, unlike other multivitamins that upset my stomach. The price is also reasonable.
Read More
Frequently Asked Questions
No FAQs are available for this product and symptom.
References
- Mere Del Aguila E, Tang XH, Gudas LJ. Retinoic acid receptor-β deletion in a model of early pancreatic ductal adenocarcinoma (PDAC) tumorigenesis. Am J Cancer Res. 2025;15:127. 10.62347/XFOT8509
- Raza Y, Yu G, Chiappone SB, Liu S, Luberto C. Fenretinide targets GATA1 to induce cytotoxicity in GATA1 positive Acute Erythroid and Acute Megakaryoblastic Leukemic cells. bioRxiv. 2025. 10.1101/2025.01.19.633759
- Motoyama M, Shigefuku R, Tanaka N, Nishizawa M, Oshio K, et al. Acyclic Retinoid Inhibits the EGFR/AKT Signaling Pathway and Cancels Cisplatin-resistant Cell Characteristics. Anticancer Res. 2025;45:433. 10.21873/anticanres.17432
- Balasundaram N, Narayanan MA, Antony LSA, Kumar SR, Anandan S. Effectiveness of Fenugreek as an Adjuvant in the Management of Oral Potentially Malignant Disorders: A Randomized Controlled Trial. J Contemp Dent Pract. 2024;25:921. 10.5005/jp-journals-10024-3773
- Piotrowsky A, Burkard M, Schmieder H, Venturelli S, Renner O, et al. The therapeutic potential of vitamins A, C, and D in pancreatic cancer. Heliyon. 2025;11:e41598. 10.1016/j.heliyon.2024.e41598
- Ye Y, Zhao Z, Mo W, Liu W, Wu L, et al. Zebrafish modeling of atypical PML-RARA isoform from acute promyelocytic leukemia patient and its implications for clinical treatment. Ann Hematol. 2025;104:171. 10.1007/s00277-024-06169-x
- Kocher HM, Sasieni P, Corrie P, McNamara MG, Sarker D, et al. Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2. BMC Cancer. 2025;25:106. 10.1186/s12885-024-13333-z
- Işlek Köklü Z, Şanverdi EL, Karadağ B, Üçişik MH, Taşkan E, et al. Combinational therapy of all-trans retinoic acid (ATRA) and sphingomyelin induces apoptosis and cell cycle arrest in B16F10 melanoma cancer cells. Turk J Biol. 2024;48:401. 10.55730/1300-0152.2715
- Aydin D, Öner Ç, Aslan Öztürk S, Çolak E. Short-term effects of retinoic acid on the proliferation of SH-SY5Y cells via mitophagy and apoptosis. Cell Mol Biol (Noisy-le-grand). 2024;70:64. 10.14715/cmb/2024.70.11.9
- Sánchez-Mendoza SE, de Deus-Wagatsuma VM, do Nascimento MC, Lima K, Machado-Neto JA, et al. All-trans retinoic acid potentiates cell death induced by quizartinib in acute myeloid leukemia with FLT3-ITD mutations. Ann Hematol. 2024;103:5405. 10.1007/s00277-024-06089-w
- Kanai M, Shinagawa A, Ota M, Virgona N, Yano T. Resveratrol Can Differentiate Human Melanoma Stem-like Cells from Spheroids Treated With All-trans Retinoic Acid. Anticancer Res. 2024;44:5283. 10.21873/anticanres.17356
- Szymczak B, Pegoraro A, De Marchi E, Grignolo M, Maciejewski B, et al. Retinoic acid-induced alterations enhance eATP-mediated anti-cancer effects in glioma cells: Implications for P2X7 receptor variants as key players. Biochim Biophys Acta Mol Basis Dis. 2025;1871:167611. 10.1016/j.bbadis.2024.167611
- Jen WY, Marvin-Peek J, Kantarjian HM, Alvarado Y, Borthakur G, et al. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer. 2025;131:e35662. 10.1002/cncr.35662
- Liu G, Quan Q, Pan L, Duan H, Zhang G, et al. Retinoic acid enhances γδ T cell cytotoxicity in nasopharyngeal carcinoma by reversing immune exhaustion. Cell Commun Signal. 2025;23:156. 10.1186/s12964-025-02161-8
- Nurseta T, Indrawan IWA, Gunawan DA, Pramudia Wardani KR. Effects Atra on MMP-9 Activity and Integrin Expression in Choriocarcinoma Culture Cell Line Bewo (ATCC CCL-98). Asian Pac J Cancer Prev. 2025;26:1027. 10.31557/APJCP.2025.26.3.1027
- Mei B, Li J, Wang D, Feng L, Huang J, et al. All-trans Retinoic Acid Sensitizes Epithelial Ovarian Cancer to PARP Inhibition after Exposure to Cisplatin. Mol Cancer Ther. 2025;24:453. 10.1158/1535-7163.MCT-24-0140
- Chu Z, Zheng W, Fu W, Liang J, Wang W, et al. Implanted Microneedles Loaded with Sparfloxacin and Zinc-Manganese Sulfide Nanoparticles Activates Immunity for Postoperative Triple-Negative Breast Cancer to Prevent Recurrence and Metastasis. Adv Sci (Weinh). 2025. 10.1002/advs.202416270
- Jin X, Tong W, Sun L, Lu S, Sun P, et al. Association of composite dietary antioxidant index with high risk of prostate cancer in middle-aged and elderly men: insights from NHANES. Front Immunol. 2025;16:1530174. 10.3389/fimmu.2025.1530174
- Agare GI, Chidike Ezeorba TP, Michael DC, Emmanuel A, Clement AO, et al. Zinc Shield: Efficacy in Mitigating Oral Mucositis in Head and Neck Cancer Patients Undergoing Radiotherapy and Chemoradiotherapy - A Systematic Review. Clin Nutr ESPEN. 2025. 10.1016/j.clnesp.2025.02.011
- Zhou B, Chen M, Hao Z, Li L, Zhang Y, et al. Zinc-copper bimetallic nanoplatforms trigger photothermal-amplified cuproptosis and cGAS-STING activation for enhancing triple-negative breast cancer immunotherapy. J Nanobiotechnology. 2025;23:137. 10.1186/s12951-025-03186-4
- Buj R, Cole AR, Danielson J, Xu J, Hurd D, et al. cancer cells outcompete macrophages for microenvironmental zinc to drive immunotherapy resistance. bioRxiv. 2025. 10.1101/2025.02.08.637227
- Chen J, Wang Y, Huang J, Yang Z, Niu H, et al. Cascade specific endogenous Fe interference and catalysis for tumor therapy with stemness suppression. Natl Sci Rev. 2025;12:nwae434. 10.1093/nsr/nwae434
- Rostami N, Nikzad A, Shaybani S, Noei H, Ghebleh A, et al. Engineering Folic Acid-Modified Nanoparticles to Enhance Letrozole's Anticancer Action. Macromol Biosci. 2025. 10.1002/mabi.202400558
- Li Y, Wang Q, Yang N, Yan H, Zhu Y, et al. Novel Folate-phenylfuran P-gp Inhibitor Conjugates for Overcoming Multidrug Resistance in MCF-7/ADR Cell. ChemMedChem. 2025. 10.1002/cmdc.202500216
- Goemaere I, Cielo A, Daniele R, Mastrotto F, De Smedt SC, et al. Nanosecond Laser Pulses Facilitating Efficient and Specific Cell Killing with Doxorubicin-Loaded Gold Nanoparticles Targeted to the Folate Receptor. Small Sci. 2025;5:2400234. 10.1002/smsc.202400234
- Patki SR, P SS, Manjappa AS, Veerachamy A, Sankaranarayanan M, et al. Identification of Active Phytochemicals to Inhibit Signal Transducer and Activator of Transcription 5A (STAT5A) Dimerization for Prostate Cancer Therapy: An In Silico Approach. Anticancer Agents Med Chem. 2025. 10.2174/0118715206367609250329195533
- Liu X, Zhang Y, Zhang P, Ge K, Zhang R, et al. Preparation of targeting nanogels for controlled delivery of 5-aminolevulinic acid triggered by matrix metalloproteinases as photodynamic therapy. Biointerphases. 2025;20. 10.1116/6.0004203
- Liu S, Yi D, Ma R, Zhang W. Folic Acid-Targeted Liposome-Based Nanoparticle Loaded with Sorafenib for Liver Cancer Therapy. Int J Nanomedicine. 2025;20:3933. 10.2147/IJN.S489777
- Farsani NK, Afshari S, Poor AS, Toutounchi A, Shahbazi Z, et al. pH-responsive mesoporous silica nanoparticles functionalized with folic acid and chitosan for targeted epirubicin delivery: In vitro and in vivo efficacy in breast cancer. Int J Biol Macromol. 2025;309:142558. 10.1016/j.ijbiomac.2025.142558
- Dash BS, Lai YC, Chen JP. Folic Acid-Conjugated Magnetic Oleoyl-Chitosan Nanoparticles for Controlled Release of Doxorubicin in Cancer Therapy. Nanomaterials (Basel). 2025;15. 10.3390/nano15060415
- Xie F, Liu N, Liu X, Feng X, Yang Z, et al. Insights into folic acid functionalization of self-assembled octenyl succinic anhydride starch micelles towards targeted delivery of selenium nanoparticles. Int J Biol Macromol. 2025;308:142352. 10.1016/j.ijbiomac.2025.142352
- Nalawade S, Narwade M, Deshmukh V, Nasir N, Wahab S, et al. Surface-modified nintedanib-loaded solid lipid nanoparticles for effective targeting of non-small cell lung cancer. Colloids Surf B Biointerfaces. 2025;251:114622. 10.1016/j.colsurfb.2025.114622
- Serag E, El-Fakharany EM, Hammad SF, El-Khouly ME. Metal-organic framework MIL-101(Fe) functionalized with folic acid as a multifunctional nanocarrier for targeted chemotherapy-photodynamic therapy. Biomater Sci. 2025. 10.1039/d4bm01738b
- Ghosh T, Mandal M, Shee M, Das TK, Mandal M, et al. Fabrication of Folic Acid-Derived Carbon Dot-Conjugated Chitosan Nanospheres as Theragnostic Agents for pH-Responsive Anticancer Drug Delivery. ACS Appl Bio Mater. 2025;8:3096. 10.1021/acsabm.4c01962
